TSI’s CSO, Houda Hachad, in collaboration with other members from the Association for Molecular Pathology (AMP) PGx Working Group has published a guideline to facilitate CYP2C19 testing for laboratories.

New report defines a two-tier categorization of alleles as part of ongoing effort to continuously improve professional pharmacogenetics practice and patient care


Newswise — BETHESDA, Md. — Feb. 27, 2018 — The Association for Molecular Pathology (AMP), the premier global molecular diagnostics professional society, today published consensus, evidence-based recommendations to aid clinical laboratory professionals when designing and validating clinical CYP2C19 assays, promote standardization of testing across different laboratories and complement existing clinical guidelines. The report, “Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology,” was released online ahead of publication in The Journal of Molecular Diagnostics.


The cytochrome P450 2C19 (CYP2C19) gene is one of the most frequently tested pharmacogenetics (PGx) genes because it is involved in the phase I metabolism of many commonly prescribed medications. However, currently available CYP2C19 tests can produce variable results due to factors such as the choice of tested alleles, targeted testing of populations with varying ethnic backgrounds, as well as the technical performance of the various platforms. The AMP PGx Working Group was established to help standardize this process by recommending variants for inclusion in clinical CYP2C19 genotyping panels.


“Considering the complex nature of clinical PGx testing and interpretation, and its impact on patient care, there is a clear, practical need for standardizing these transformative assays,” said Victoria M. Pratt, PhD, Associate Professor of Medical and Molecular Genetics at Indiana University School of Medicine and AMP PGx Working Group Chair. “The AMP PGx Working Group started with CYP2C19 genotyping panels due to the widespread adoption of these tests and our desire to help physicians, pharmacists, researchers, and other stakeholders better understand what these panels include and what the test results mean.”


read more

To read the guideline, visit: https://doi.org/10.1016/j.jmoldx.2018.01.011